Michael Brines

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9168947/publications.pdf

Version: 2024-02-01

92	10,215	53660 45	51492 86
papers	citations	h-index	g-index

94	94	94	5922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Control of inflammation using non-invasive neuromodulation: past, present and promise. International Immunology, 2022, 34, 119-128.	1.8	11
2	Editorial: Erythropoietin and Its Analogues as Therapeutics for Neurological Diseases. Frontiers in Pharmacology, 2022, 13, 841538.	1.6	0
3	The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences, 2022, 23, 55.	1.8	1
4	Famotidine exerts antiâ€inflammatory effects via a vagus nerveâ€dependent mechanism. FASEB Journal, 2022, 36, .	0.2	1
5	The erythropoietinâ€derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2202-2210.	2.9	2
6	Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cell Transplantation, 2021, 30, 096368972110397.	1.2	5
7	HMGB1 released from nociceptors mediates inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	34
8	Systemic administration of choline acetyltransferase decreases blood pressure in murine hypertension. Molecular Medicine, 2021, 27, 133.	1.9	5
9	Neurons Are a Primary Driver of Inflammation via Release of HMGB1. Cells, 2021, 10, 2791.	1.8	13
10	Corneal confocal microscopy: ready for prime time. Australasian journal of optometry, The, 2020, 103, 265-277.	0.6	73
11	Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 2020, 104, 2048-2058.	0.5	4
12	A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine, 2020, 9, 2225.	1.0	7
13	Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia, 2019, 62, 1478-1487.	2.9	91
14	The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic. Experimental Eye Research, 2019, 182, 144-155.	1.2	17
15	Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Scientific Reports, 2018, 8, 4734.	1.6	70
16	Activation of the EPOR-Î² common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 632-639.	1.8	14
17	Improvement of Metabolic Function after Intra-Portal Allogeneic Islet Transplantation Using Induction Treatment of the Non-Hematopoetic Erythropoietin Analogue Cibinetide in a Mouse Model. Transplantation, 2018, 102, S747-S748.	0.5	0
18	Extrahematopoietic Actions of Erythropoietin. , 2018, , 411-428.		0

#	Article	IF	Citations
19	Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific Reports, 2017, 7, 13012.	1.6	9
20	Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsies. Journal of Pain Research, 2017, Volume 10, 2057-2065.	0.8	13
21	Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. , 2017, 58, BIO52.		84
22	Functional and symptomatic burden of small fiber neuropathy in sarcoidosis. , 2017, , .		0
23	Specific ligand for the innate repair receptor, ARA290, attenuates pulmonary hypertension in an elastase-induced murine model of emphysema. , 2017, , .		1
24	A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation, 2016, 100, 554-562.	0.5	21
25	Cornea nerve fiber quantification and construction of phenotypes in patients with fibromyalgia. Scientific Reports, 2016, 6, 23573.	1.6	48
26	Targeting the innate repair receptor to treat neuropathy. Pain Reports, 2016, 1, e566.	1.4	9
27	ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitorsâ€™ Angiogenic Potential and Homing Ability. Shock, 2016, 46, 390-397.	1.0	20
28	An Engineered Innate Repair Receptor Agonist, ARA 290, Protects Rat Islets from Cytokine-induced Apoptosis. Journal of Diabetes & Metabolism, 2016, 7, .	0.2	1
29	ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Molecular Medicine, 2015, 21, 969-978.	1.9	10
30	Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. , 2015, 151, 32-40.		71
31	Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. Journal of Molecular Medicine, 2015, 93, 199-210.	1.7	27
32	The mast cell plays a central role in the immune system of teleost fish. Molecular Immunology, 2015, 63, 3-8.	1.0	43
33	ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine, 2014, 20, 658-666.	1.9	115
34	Discovery of a Master Regulator of Injury and Healing: Tipping the Outcome from Damage toward Repair. Molecular Medicine, 2014, 20, S10-S16.	1.9	17
35	ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs, 2014, 23, 541-550.	1.9	33
36	ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response. Molecular Pain, 2014, 10, 1744-8069-10-13.	1.0	29

#	Article	IF	Citations
37	Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3513-3518.	3.3	49
38	Erythropoietin and Engineered Innate Repair Activators. Methods in Molecular Biology, 2013, 982, 1-11.	0.4	10
39	The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs, 2013, 1, 77-87.	0.5	7
40	Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the Î²-common receptor. Kidney International, 2013, 84, 482-490.	2.6	71
41	Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarctionâ€“Dilated Cardiomyopathy. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 446-456.	1.3	20
42	Suppression of Coronary Atherosclerosis by Helix B Surface Peptide, a Nonerythropoietic, Tissue-Protective Compound Derived from Erythropoietin. Molecular Medicine, 2013, 19, 195-202.	1.9	25
43	ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. Molecular Medicine, 2013, 19, 334-345.	1.9	78
44	Ketamine Does Not Produce Relief of Neuropathic Pain in Mice Lacking the Î²-Common Receptor (CD131). PLoS ONE, 2013, 8, e71326.	1.1	15
45	The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs, 2013, 1, 77-87.	0.5	11
46	The Receptor That Tames the Innate Immune Response. Molecular Medicine, 2012, 18, 486-496.	1.9	111
47	Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. Molecular Medicine, 2012, 18, 719-727.	1.9	35
48	Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Molecular Medicine, 2012, 18, 1430-1436.	1.9	89
49	A Nonerythropoietic Peptide that Mimics the 3D Structure of Erythropoietin Reduces Organ Injury/Dysfunction and Inflammation in Experimental Hemorrhagic Shock. Molecular Medicine, 2011, 17, 883-892.	1.9	27
50	A Small Nonerythropoietic Helix B Surface Peptide Based upon Erythropoietin Structure Is Cardioprotective against Ischemic Myocardial Damage. Molecular Medicine, 2011, 17, 194-200.	1.9	50
51	Promises and Pitfalls in Erythopoietin-Mediated Tissue Protection. Journal of Investigative Medicine, 2011, 59, 1073-1082.	0.7	40
52	Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia. Experimental Neurology, 2011, 232, 126-135.	2.0	26
53	Intervention With an Erythropoietin-Derived Peptide Protects Against Neuroglial and Vascular Degeneration During Diabetic Retinopathy. Diabetes, 2011, 60, 2995-3005.	0.3	105
54	ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Relief of Neuropathic Pain. Anesthesiology, 2011, 115, 1084-1092.	1.3	44

#	Article	IF	Citations
55	Anthropometric Variables Accurately Predict Dual Energy X-Ray Absorptiometric-Derived Body Composition and Can Be Used to Screen for Diabetes. PLoS ONE, 2011, 6, e24017.	1.1	6
56	Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14357-14362.	3.3	51
57	The Therapeutic Potential of Erythropoiesis-Stimulating Agents for Tissue Protection: A Tale of Two Receptors. Blood Purification, 2010, 29, 86-92.	0.9	69
58	Erythropoietin: not just about erythropoiesis. Lancet, The, 2010, 375, 2142.	6.3	48
59	Nonerythropoietic Tissue Protective Compounds Are Highly Effective Facilitators of Wound Healing. Molecular Medicine, 2009, 15, 235-241.	1.9	44
60	Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1602-1607.	3.3	113
61	Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?. Heart Failure Reviews, 2008, 13, 415-423.	1.7	38
62	Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Experimental Neurology, 2008, 209, 161-170.	2.0	35
63	Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10925-10930.	3.3	280
64	TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6185-6190.	3.3	100
65	Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 552-563.	2.4	128
66	Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo. Molecular Medicine, 2006, 12, 153-160.	1.9	82
67	Carbamylated Erythropoietin Reduces Radiosurgically-Induced Brain Injury. Molecular Medicine, 2006, 12, 74-80.	1.9	56
68	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 172, 27-37.	1.1	103
69	Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17531-17536.	3.3	50
70	Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity. Clinical Cancer Research, 2006, 12, 2607-2612.	3.2	85
71	Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 999-1005.	1.3	87
72	Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. Journal of Neurosurgery: Spine, 2006, 4, 310-318.	0.9	82

#	Article	IF	Citations
73	Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5965-5970.	3.3	129
74	Erythropoietin in Spinal Cord Injury. , 2006, , 147-164.		3
75	Emerging biological roles for erythropoietin in the nervous system. Nature Reviews Neuroscience, 2005, 6, 484-494.	4.9	480
76	From The Cover: Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16379-16384.	3.3	117
77	A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2046-2051.	3.3	231
78	Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?. Neuroscientist, 2004, 10, 93-98.	2.6	95
79	Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 823-828.	3.3	238
80	Erythropoietin mediates tissue protection through an erythropoietin and common Â-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14907-14912.	3.3	657
81	Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?. Critical Care, 2004, 8, 337.	2.5	75
82	Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic. Science, 2004, 305, 239-242.	6.0	775
83	Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis. Journal of Experimental Medicine, 2003, 198, 971-975.	4.2	481
84	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4802-4806.	3.3	556
85	Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6741-6746.	3.3	416
86	Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9450-9455.	3.3	351
87	Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10659-10664.	3.3	397
88	Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2258-2263.	3.3	435
89	Recombinant Human Erythropoietin for Neuroprotection: What Is the Evidence?. Clinical Breast Cancer, 2002, 3, S109-S115.	1.1	48
90	Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial. Molecular Medicine, 2002, 8, 495-505.	1.9	932

#	Article	IF	Citations
91	Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Research, 2002, 952, 128-134.	1.1	326
92	Erythropoietin therapy for acute stroke is both safe and beneficial. Molecular Medicine, 2002, 8, 495-505.	1.9	302